Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D89.832Cytokine release syndrome, grade 2

✓ Billable / specificNot a principal dx

D89.832 is a valid, billable ICD-10-CM code for cytokine release syndrome, grade 2. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2021 (effective October 1, 2020). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D89.832

D89.832 is the ICD-10-CM diagnosis code for Cytokine release syndrome, grade 2. It belongs to category D89 (other disorders involving the immune mechanism, not elsewhere classified), block D80-D89 (certain disorders involving the immune mechanism) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D89.83 (Cytokine release syndrome), D89.832 is specifically for Cytokine release syndrome, grade 2. Related codes cover grade 1 (D89.831), grade 3 (D89.833), grade 4 (D89.834), grade 5 (D89.835) and grade unspecified (D89.839).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It was added in FY2021, effective October 1, 2020.

Notes that apply from higher levels

Instructions written at a parent level also apply to D89.832.

› From D89.83 Cytokine release syndrome
Code first
  • underlying cause, such as:
  • complications following infusion, transfusion and therapeutic injection (T80.89-)
  • complications of transplanted organs and tissue (T86.-)
Use additional code
  • code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)
  • code to identify associated manifestations
› From D89 Other disorders involving the immune mechanism, not elsewhere classified
Excludes1
  • hyperglobulinemia NOS (R77.1)
  • monoclonal gammopathy (of undetermined significance) (D47.2)
Excludes2
  • transplant failure and rejection (T86.-)

Broader instructions also apply from D80-D89 Certain disorders involving the immune mechanism and Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Alphabetic index entries

1 entries

Terms in the official ICD-10-CM index that lead to D89.832.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2021 (effective 10/1/2020): Added
  • No changes since FY2021.

Common questions about D89.832

Is D89.832 billable?

Yes. D89.832 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D89.832 be used as a principal diagnosis?

No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

Is D89.832 a CC or MCC?

No. D89.832 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does D89.832 group to?

D89.832 is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.